Idorsia says DEA proposes moving dual orexin insomnia drugs to Schedule V

• DEA to propose reclassifying dual orexin receptor antagonists from Schedule IV to Schedule V under the Controlled Substances Act.
• Proposal expected to publish later today; 30-day public comment period before a final DEA decision.
• DEA cited HHS review, stating the drug class does not produce physical or psychological dependence.
• Idorsia sees Schedule V as a step toward fewer US prescribing restrictions; it plans to submit comments, seeking full descheduling.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110100OMX_____CNEWS_EN_GNW1001256967_en) on August 11, 2026, and is solely responsible for the information contained therein.